The Role of Psychedelic-Assisted Therapies in Treating Depression
August 30, 2024 DOI: 10.64239/pi-vl8206 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Topics | Depression Psychedelic-assisted therapy |
| Key findings | Psychedelic-assisted therapy shows rapid symptom reduction for depression but also a dose-dependent increase in suicidal ideation and behavior in the largest trial. |
Abstract
Psychedelic-assisted therapy trials for depression have shown robust, rapid symptom reduction lasting weeks to months after treatment in some studies. The largest trial to date found a dose-dependent increase in suicidal ideation and behavior, suggesting potential risks. Psychedelics show promise in addressing depression and anxiety related to terminal illnesses.
Comparable studies
Other narrative reviews on depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synaptic Dysfunction in Depression: Potential Therapeutic Targets | 2012 | Review | |
| Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse | 2003 | Review | |
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| Sudarshan Kriya Yogic Breathing in the Treatment of Stress, Anxiety, and Depression: Part II—Clinical Applications and Guidelines | 2005 | Review |